secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2023-01-04T23:59:59+00:00
Accession:  0001140361-23-000340
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eterna Therapeutics to transfer Nasdaq listing after equity shortfall; Dr. Angel appointed CEO
--------------------------------------------------------------------------------

- Stockholders' equity of $8.8M missed Nasdaq Global Market's $10M minimum; Board authorized transfer to Capital Market on Dec 29, 2022, applied Jan 2, 2023.
- Dr. Matthew Angel appointed President & CEO effective Jan 1, 2023; base salary $350k, signing bonus $210,959, performance bonus of 2% of gross proceeds from licensing etc.
- Option grant to increase Dr. Angel's total options to 5% of outstanding shares; 50% vested on Start Date, remainder over 36 months.
- Related party: Factor Bioscience (64% owned by Angel) receives $5M initial fee under MSA; license amended, option with Exacis terminated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000114036123000340/0001140361-23-000340-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000114036123000340/brhc10046238_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-000340

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer